PolyPid Posts $7.8M Q2 Loss, $6.6M Cash; $5.8M Raised in July Extends Runway to Q2 2027
PYPD sits 46% above its 52-week low of $3.06 on light trading volume (0.4× avg).
Summary
PolyPid reported a Q2 net loss of $7.8M with only $6.6M in cash at quarter-end, but raised $5.8M in July through warrant exercises and ATM sales, extending its cash runway into Q2 2027. This follows the transformative Azurity licensing deal and FDA Priority Review acceptance for D-PLEX100, which brought in $30M in upfront and near-term milestones. The financial update is critical given the company's pre-revenue stage and the need to fund operations through the November 28 PDUFA date and potential early 2027 launch. The conference call at 8:30 AM ET may provide additional color on spending and milestone timing.
At the time of this announcement, PYPD was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.3M. The 52-week trading range was $3.06 to $5.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.